Viela Bio Announces Pricing of Public Offering of Common Stock
27 mai 2020 22h40 HE
|
Viela Bio
GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
Viela Bio Announces Proposed Public Offering of Common Stock
26 mai 2020 07h23 HE
|
Viela Bio
GAITHERSBURG, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
13 mai 2020 16h15 HE
|
Viela Bio
GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today...
Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
13 mai 2020 16h10 HE
|
Viela Bio
-Safety profile comparable to placebo control- -Potent depletion of plasmacytoid dendritic cells in peripheral blood and skin biopsies- -Dose-dependent improvements in Cutaneous Lupus Erythematosus...
Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020
06 mai 2020 07h00 HE
|
Viela Bio
GAITHERSBURG, Md., May 06, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today...
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
30 avr. 2020 16h15 HE
|
Viela Bio
GAITHERSBURG, Md., April 30, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
25 mars 2020 16h15 HE
|
Viela Bio
GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
18 mars 2020 07h00 HE
|
Viela Bio
GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today...
Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
11 déc. 2019 07h00 HE
|
Viela Bio
GAITHERSBURG, Md., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
14 nov. 2019 16h00 HE
|
Viela Bio
GAITHERSBURG, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...